Cancers & treatments·Regimen libraryMaintenance

Olaparib maintenance

Checked 2026-09-09

Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum

One cycle

every 28 days × 2 · about 8 weeks in total

28-day cycle × 2 years (SOLO-1) or until progression (about 8 weeks)Oral Daily oral course

Components

Drug	Dose	Route	Days	Note
Olaparib Small-molecule PARP inhibitor	300 mg twice daily	Oral	D1-28

Cycles

2 years (SOLO-1) or until progression

28-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Anaemia is the commonest dose-limiting toxicity; check blood counts monthly for the first year.

Used in

Ovarian cancer Prostate cancer Pancreatic ductal adenocarcinoma

Trials

SOLO-1 PROfound POLO PROpel

Products

Olaparib

Source

SOLO-1, NEJM 2018

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.